Oncolytic Viral Therapy Development for Leukemia

Oncolytic viral therapy refers to using a replication-competent virus to treat cancer. It is recognized that oncolytic viruses can function through multiple roles, including mutations in the tumor environment and combined changes in the action of immune effectors. Alfa Cytology is a world leader in cancer therapy development. With our extensive experience and advanced platform, we can provide the best solutions for oncolytic viral therapy development.

Overview of Oncolytic Viral Therapy

Because hematological malignancies are difficult to treat and have a high recurrence rate, and there is evidence of contaminated cancer cells in transplantation, removal of contaminated cancer cells is an effective way to improve overall survival after transplantation. Due to the special properties of OVS, they are considered ideal scavengers for hematological malignancies. For example, oncolytic viruses can re-engineer the pro-tumor environment into an inflammatory and anti-tumor environment by affecting tumor-associated cells such as fibroblasts, macrophages, endothelial cells, and neutrophils. Some of the oncolytic virus types in the study and the types of cancers these viruses correspond to are listed below.

Mechanisms of Viral Oncolysis

Oncolytic viruses selectively destroy tumor cells through two main mechanisms.

• Direct oncolytic (lysis of infected tumor cells).
• Induce immune-mediated tumor cell death by enhancing the immune response, thus forming anti-tumor immunity.

Modern genetic engineering techniques can increase the tumor specificity of viruses and regulate their immunogenicity by enhancing their replication activity in tumor cells. At present, the development and research of novel oncolytic virus strains are developing rapidly.

Fig. 1 Oncolytic virus anti-tumor mechanism of action. (Lovatt, C. & Parker, A.L.; 2023)

Development of Oncolytic Viral Therapy for Leukemia

The natural oncolytic properties of viruses were discovered more than a century ago, and advances in the understanding of molecular mechanisms and viral biology have facilitated the development of effective and highly selective oncolytic strains. Oncolytic viruses can continuously infect tumor cells and eliminate small residual lesions, so oncolytic virus therapy has great potential in leukemia, such as AML.

With our specialized laboratories and development platform, Alfa Cytology provides customized, standardized, reliable, and high-quality oncolytic virus therapy development services for leukemia.

Why Choose Us?

Alfa Cytology is committed to the research and study of cancer and provides one-stop services. Our cancer experts have many years of experience in the latest therapies for oncolytic viral therapy. If you are interested in our service, please contact us for more information.